MGNX Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.70 |
| 52 Week High | US$21.88 |
| 52 Week Low | US$3.14 |
| Beta | 2.08 |
| 11 Month Change | 14.55% |
| 3 Month Change | -13.75% |
| 1 Year Change | -20.60% |
| 33 Year Change | -81.93% |
| 5 Year Change | -71.27% |
| Change since IPO | -85.19% |
Recent News & Updates
Recent updates
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18Shareholder Returns
| MGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.8% | 5.6% | 4.2% |
| 1Y | -20.6% | 19.5% | 24.4% |
Return vs Industry: MGNX underperformed the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: MGNX underperformed the US Market which returned 22% over the past year.
Price Volatility
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MGNX's share price has been volatile over the past 3 months.
Volatility Over Time: MGNX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 339 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics, Inc. Fundamentals Summary
| MGNX fundamental statistics | |
|---|---|
| Market cap | US$232.07m |
| Earnings (TTM) | -US$136.37m |
| Revenue (TTM) | US$41.02m |
5.7x
P/S Ratio-1.7x
P/E RatioIs MGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNX income statement (TTM) | |
|---|---|
| Revenue | US$41.02m |
| Cost of Revenue | US$176.48m |
| Gross Profit | -US$135.46m |
| Other Expenses | US$914.00k |
| Earnings | -US$136.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | -330.24% |
| Net Profit Margin | -332.47% |
| Debt/Equity Ratio | 0% |
How did MGNX perform over the long term?
See historical performance and comparison